Four StitchR-based dual-viral reconstitution strategies by combining high-efficiency AAV serotypes with neuron- or glia-specific promoters expand the valuable AAV toolbox and offer crucial technical support for targeted delivery of large transgenes to defined neural cell populations, holding great significance for basic neuroscience research and potential therapeutic applications.
Abstract
Dual adeno-associated virus (AAV) vector reconstitution has become an indispensable technique for delivering large genes in neuroscience and gene therapy. A novel technology termed StitchR addresses the challenge of low efficiency in dual-AAV reconstruction, yet related tools enabling targeted gene delivery to specific neural cell populations remain insufficiently developed. Herein, we developed four StitchR-based dual-viral reconstitution strategies by combining high-efficiency AAV serotypes with neuron- or glia-specific promoters. Specifically, the AAV11-hSyn-driven StitchR strategy achieved specific transduction of local neurons and their upstream projection neurons (≥ 94.44% specificity); the AAV11-GfaABC1D-driven strategy realized astrocyte-specific transduction (approximately 98.25% specificity); and the AAV11-mIBA1-driven strategy enabled microglia-specific transduction (100% specificity). Furthermore, by incorporating the blood–brain barrier (BBB)-penetrating AAVhu.32-PLUS into the hSyn-driven system, we established a modified strategy that allows brain-wide neuronal transduction. Finally, we confirmed that the StitchR-based dual-viral reconstitution strategy can achieve efficient functional reconstitution of large transgenes in neural cells. Collectively, these dual-AAV delivery strategies expand the valuable AAV toolbox and offer crucial technical support for targeted delivery of large transgenes to defined neural cell populations, holding great significance for basic neuroscience research and potential therapeutic applications.
Evidence that cell-type-specific promoters lose fidelity when paired with neurogenic transgene payloads and that published in vivo reprogramming efficiencies may be substantially confounded by promoter leakage in the absence of formal lineage tracing are synthesized.
M. Abdelnaby, A. Galiakberova, E. Dashinimaev· International Journal of Mol...· 0 citations
A novel approach to detarget liver transduction is developed by transiently downregulating the expression of key entry factors in this tissue using GalNac-siRNAs prior to AAV9 administration, which blunted hepatic transduction but also redirected the vector to other transduction-permissive tissues.
K. Kubek-Luck, J. Velazquez, Xiao-Rui Yao et al.· Molecular Therapy· 0 citations
A streamlined three-dimensional spheroid platform optimized for evaluating AAV potency, transgene expression kinetics, and serotype-specific transduction efficacy across diverse cell lines is described and establishes its utility as a scalable and physiologically relevant system for preclinical gene therapy evaluation...
Susana S. Najera, R. Mazor· Journal of Visualized Experi...· 0 citations
It is shown that systemic AAV administration provides potent delivery and uniform transduction of cardiac tissue, outperforming localized injection techniques and establishing an effective AAV approach for transgene transfer into the mouse heart and promote the development of gene therapy for cardiac disorders.
I. Galkin, V. Skopenkova, Maria Y. Shubina et al.· BioTech· 0 citations
Adeno-associated viruses (AAVs) provide a versatile tool for labeling neurons in the Xenopus central nervous system across developmental stages. AAV-mediated transgene expression is long-lasting and stable, enabling robust labeling of neuronal populations without genomic integration and without the need to generate tra...
David Vijatovic, Lora B. Sweeney· Methods in molecular biology· 0 citations
Neural organoids provide tractable models of human brain development, function, and disease, but adeno-associated viral vector (AAV)-based gene delivery is limited by inefficient transduction and insufficient comparative evaluation of the natural and engineered capsids. Here, we evaluated seven AAV capsids (AAV-2, -6,...